Otonomy, Inc. Logo
Otonomy Reports Second Quarter 2019 Financial Results and Provides Corporate Update
August 01, 2019 16:20 ET | Otonomy, Inc.
Clinical-stage programs on track with results expected from three trials in 2020Current capital funds operations into 2021 Conference call and webcast today at 4:30 p.m. EDT SAN DIEGO, Aug. 01,...
Otonomy, Inc. Logo
Otonomy to Report Second Quarter 2019 Financial Results and Provide Corporate Update
July 25, 2019 16:05 ET | Otonomy, Inc.
SAN DIEGO, July 25, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy, Inc. Logo
Otonomy to Present at the Raymond James Life Sciences and MedTech Conference
June 12, 2019 08:00 ET | Otonomy, Inc.
SAN DIEGO, June 12, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy, Inc. Logo
Otonomy Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 06, 2019 16:17 ET | Otonomy, Inc.
OTO-313 Phase 1/2 trial in tinnitus initiated; results expected in first half of 2020OTIPRIO® co-promotion agreement completed with Glenmark TherapeuticsOTIVIDEX™ Phase 3 trial in Ménière’s disease on...
Otonomy, Inc. Logo
Otonomy Initiates Phase 1/2 Clinical Trial of OTO-313 in Tinnitus
April 11, 2019 07:30 ET | Otonomy, Inc.
SAN DIEGO, April 11, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Otonomy, Inc. Logo
Otonomy to Present Results for AuriPro(TM) Phase 3 and OTO-104 Phase 2b Clinical Trials at 2015 AAO-HNSF Annual Meeting
September 24, 2015 07:30 ET | Otonomy, Inc.
SAN DIEGO, Sept. 24, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...